Adverum Biotechnologies Inc (ADVM)

Precedente Chiudi:

$9.19

Aprire:

$9.29

Volume 24 ore:

811.48K

Capitalizzazione di mercato:

$197.79M

Reddito:

-

Utile/perdita netta:

$-117.17M

Rapporto P/E:

-7.1654

EPS:

-1.33

Flusso di cassa netto:

$-91.71M

1 W Prestazione:

-15.96%

1M Prestazione:

-32.60%

6M Prestazione:

+903.26%

1 anno Prestazione:

+1,116%

Intervallo 1D:

$8.76

$9.964

Portata 52W:

$0.721

$17.65

Adverum Biotechnologies Inc Stock (ADVM) Company Profile

Nome

Adverum Biotechnologies Inc

Settore

Healthcare (1199)

Industria

Biotechnology (687)

Telefono

650-272-6269

Indirizzo

1035 O'Brien Drive, Suite A, Menlo Park, CA

Dipendente

96

Cinguettio

@adverumbio

Prossima data di guadagno

2024-05-09

Ultimi documenti SEC

ADVM's Discussions on Twitter

Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2022-07-07	Aggiornamento	Truist	Hold → Buy
2021-07-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2021-05-03	Downgrade	SVB Leerink	Outperform → Mkt Perform
2021-04-29	Downgrade	Chardan Capital Markets	Buy → Neutral
2021-04-29	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2021-04-29	Downgrade	Truist	Buy → Hold
2020-12-16	Iniziato	UBS	Neutral
2020-11-12	Aggiornamento	Raymond James	Underperform → Mkt Perform
2020-06-26	Downgrade	Raymond James	Mkt Perform → Underperform
2020-05-13	Iniziato	RBC Capital Mkts	Outperform
2020-05-05	Aggiornamento	SunTrust	Hold → Buy
2020-04-28	Iniziato	Goldman	Buy
2020-03-16	Iniziato	SVB Leerink	Outperform
2020-02-10	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2020-02-10	Aggiornamento	Chardan Capital Markets	Neutral → Buy
2019-10-15	Reiterato	Chardan Capital Markets	Neutral
2019-09-13	Reiterato	Chardan Capital Markets	Neutral
2019-06-14	Ripresa	Raymond James	Mkt Perform
2018-11-02	Downgrade	Raymond James	Outperform → Mkt Perform
2018-11-02	Downgrade	SunTrust	Buy → Hold
2018-09-21	Iniziato	Cantor Fitzgerald	Overweight
2018-08-30	Iniziato	SunTrust	Buy
2018-02-15	Ripresa	Piper Jaffray	Overweight
2017-10-12	Iniziato	Raymond James	Outperform

Mostra tutto

Adverum Biotechnologies Inc Borsa (ADVM) Ultime notizie

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

GlobeNewswire Inc.

Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?

Zacks Investment Research

Down -24.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)

Zacks Investment Research

Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?

Zacks Investment Research

How Adverum (ADVM) Stock Stands Out in a Strong Industry

Zacks Investment Research

Down -28.72% in 4 Weeks, Here's Why Adverum Biotechnologies (ADVM) Looks Ripe for a Turnaround

Zacks Investment Research

Adverum Biotechnologies Inc Azioni (ADVM) Dati Finanziari

Adverum Biotechnologies Inc (ADVM) Reddito netto 2024

Adverum Biotechnologies Inc (ADVM) Flusso di cassa 2024

Adverum Biotechnologies Inc (ADVM) Utile per azione 2024

Adverum Biotechnologies Inc Azioni (ADVM) insider trading